RxDoctor Payments Data

Betty Mitchell, NP

Family · O Fallon, MONPI 1649725987

Payments from drug & device makers

$1,293in general payments, 2019–2025

Across 13 payments — averaging $99.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$341
  • AstraZeneca$312
  • Edwards Lifesciences$124
  • Viiv Healthcare Company$118
  • GSK$109
  • Exeltis, USA Inc.$102
  • plus $187 from 2 others

What the payments were for

  • Food & beverage$1,292100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,293 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$38,994
Medicare patients
248
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$28,063
ArexvyRsvpref3 Antigen/As01e/Pf34$7,652
Fluticasone Propionate82$951
Atorvastatin Calcium97$882
Levothyroxine Sodium123$851
Pantoprazole Sodium44$825
Doxycycline Hyclate78$752
Metoprolol Succinate36$730
Omeprazole64$706
Gabapentin42$693
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav81$673
Diclofenac Sodium18$659
Rosuvastatin Calcium76$599
Duloxetine Hcl21$576
Potassium Chloride19$559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$341$28,06320 claims
GSKArexvy$109$7,65234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.

Other family in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →